STOCK TITAN
  1. Home
  2. News
  3. XXII

22nd Century Group Inc - XXII STOCK NEWS

Welcome to our dedicated news page for 22nd Century Group (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22nd Century Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 22nd Century Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 22nd Century Group's position in the market.

News
22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
22nd Century Group, Inc. reported third quarter 2023 net revenue of $17.8 million. VLN® availability expanded to over 4,550 stores in 19 states. FDA menthol ban regulation is undergoing review. GVB bulk ingredient volume of 49,000 kg shipped. Operating cost reductions of over $15 million initiated. Principal debt balances reduced by $8.1 million in October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.89%
Tags
earnings
-
News
22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB
Rhea-AI Summary
22nd Century Group supports FDA's move to ban menthol in cigarettes and flavored cigars
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
News
22nd Century Group (XXII) Reduces Debt by $8.1 Million
Rhea-AI Summary
22nd Century Group, Inc. has reduced the outstanding principle of its Senior Secured Credit Facility by 37% through the transfer of non-core and previously restricted assets. The reduction reflects a waiver and repayment of the $7.5 million minimum cash balance required under terms of the original debenture agreements. The company also assigned an existing promissory note to further reduce the debt. The remaining principal loan balance of $14.0 million will be due at maturity in 2026. The company also announced a public offering with $5.25 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
News
22nd Century Announces Pricing of $5.25 Million Public Offering
Rhea-AI Summary
22nd Century Group, Inc. announces pricing of public offering of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
offering
-
News
22nd Century Announces Proposed Public Offering
Rhea-AI Summary
22nd Century Group, Inc. plans to offer and sell shares of its common stock and warrants in a public offering. The offering is subject to market conditions and the actual terms are yet to be determined. The proceeds will be used for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
offering
-
News
22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States
Rhea-AI Summary
22nd Century Group, Inc. announces that its FDA authorized VLN® reduced nicotine content cigarettes are now available at over 1,200 drug store locations across five states, bringing the total number of stores to over 4,000. VLN® users report a positive experience and a reduction in usage of their regular brand. The company continues to expand access to VLN® products in new states and retail chains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.6%
Tags
none
News
22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets
Rhea-AI Summary
22nd Century Group, Inc. initiates process to evaluate strategic alternatives for tobacco assets
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
none
-
News
22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
22nd Century Group, Inc. reported a 62% increase in net revenues for Q2 2023, reaching $23.4 million. The company launched VLN® sales in California, Texas, and Florida, and delivered record GVB ingredient volumes. They also initiated an operating cost reduction program targeting $15+ million in annualized savings. The revenue outlook for 2023 has been updated to a range of $80 million to $90 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.73%
Tags
earnings
-
News
22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023
Rhea-AI Summary
22nd Century Group, Inc. will host a webcast on August 14, 2023, to discuss its 2023 second quarter results. The webcast will include a review of financial results and progress made in each of the Company’s three franchises.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
earnings
News
22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023
Rhea-AI Summary
22nd Century Group, Inc. (Nasdaq: XXII) will host a live webcast on August 14, 2023, to discuss its 2023 first quarter results. The webcast will feature John Miller, interim CEO, and Hugh Kinsman, CFO, reviewing financial results and progress in the Company’s three franchises. A Q&A session will follow, accessible on the Investor Relations section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
earnings
Stock XXII logo
22nd Century Group Inc

Nasdaq:XXII

XXII Rankings

N/A Ranked by Market Cap
#5536 Ranked by Stock Gains
N/A Ranked by Dividends

XXII Stock Data

9.41M
3.28M
0.65%
6.58%
5.51%
Tobacco Manufacturing
Manufacturing
Link
United States
Mocksville

About XXII

with the mission of reducing the harm caused by smoking, 22nd century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. goodrich tobacco company and hercules pharmaceuticals are wholly-owned subsidiaries focusing on (i) premium cigarettes and potentially reduced risk tobacco products (with up to 97% less nicotine than conventional cigarettes), and (ii) the x-22 prescription smoking cessation aid in development. 22nd century's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.